NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Good find... any ideas as to what might be considered "major" in a regulatory submission that might increase their operating expenses?

Considering the "hijack" theory of Dan's... it's been thrown out there previously, initially when Flipper found "The Cancer Letter" interview of Dr. Pazdur... but Dan used the word hijack, which I kinda like.

Anyway... just a thought... what if the FDA did take a thorough peek at the trial data, didn't tell the company what they were looking at in order to keep the blind on...

(Linda L. states they were still blinded as of October 15 - remember, that's the day that her fellow academics furtively called all their hedge fund buddies telling them to sell NWBO after she spoke bullishly on L's progress - according to Adam)

... and then asked the company to make some sort of "major regulatory submission(s)"?

One thing that's been rattling around in my head... is what if the FDA requested that all the trial patient's tumors (presuming there was something left after the vaccine was made) be tested via deep sequencing of the T cell receptors by Adaptive Biotechnologies? If the FDA peeked, saw some patients were living much longer than normal, and wanted to know what might be different with those patients from those who weren't living as long?

I'd think that would be pretty costly. Not that your typical regulatory submission wouldn't be expensive. It was just a thought.